Related Experiment Video

Updated: Jan 2, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

995

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Grace Wakabayashi1, Yu-Ching Lee2, Frank Luh3

  • 1Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan, 110.

Journal of Biomedical Science
|December 6, 2019
PubMed

Insights

Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death receptor-1 (PD-1)/PD-L1 are revolutionizing cancer treatment. This review covers PD-1/PD-L1 blockade therapies, clinical trials, and predictive biomarkers for immunotherapy success.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Cancer immunotherapy has seen dramatic advances, with immune checkpoint inhibitors emerging as a key therapeutic strategy.
  • Inhibitors targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) show significant clinical benefits.

Purpose of the Study:

  • To provide background information on therapies involving PD-1/PD-L1 blockade.
  • To offer an overview of current clinical trials utilizing these immunotherapies.
  • To present recent advances in predictive biomarkers for cancer immunotherapy.

Main Methods:

  • Literature review of immune checkpoint inhibitor therapies.
  • Analysis of current clinical trial data for PD-1/PD-L1 blockade.
  • Synthesis of recent research on predictive biomarkers in cancer immunotherapy.

Main Results:

  • PD-1/PD-L1 blockade therapies demonstrate impressive clinical benefits in various cancer types.
  • Ongoing clinical trials continue to explore the efficacy and safety of these agents.
  • Predictive biomarkers are crucial for identifying patients likely to respond positively to immunotherapy.

Conclusions:

  • Immune checkpoint inhibitors, particularly PD-1/PD-L1 blockade, represent a significant advancement in cancer treatment.
  • Understanding current clinical trials and predictive biomarkers is essential for optimizing immunotherapy outcomes.
  • Further research into biomarkers will enhance the personalized application of cancer immunotherapies.
Keywords:
Cancer immunotherapyCheckpoint inhibitorPD-1 PD-L1 signaling

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.1K
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
897
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K